212 related articles for article (PubMed ID: 25128026)
1. Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Qin X; Wu Q; Lin L; Sun A; Liu S; Li X; Cao X; Gao T; Luo P; Zhu X; Wang X
Mol Neurobiol; 2015 Aug; 52(1):187-95. PubMed ID: 25128026
[TBL] [Abstract][Full Text] [Related]
2. Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress.
Huang HJ; Wang YT; Lin HC; Lee YH; Lin AM
Mol Neurobiol; 2018 Jan; 55(1):138-144. PubMed ID: 28822080
[TBL] [Abstract][Full Text] [Related]
3. Soluble Epoxide Hydrolase Inhibition Attenuates Excitotoxicity Involving 14,15-Epoxyeicosatrienoic Acid-Mediated Astrocytic Survival and Plasticity to Preserve Glutamate Homeostasis.
Kuo YM; Hsu PC; Hung CC; Hu YY; Huang YJ; Gan YL; Lin CH; Shie FS; Chang WK; Kao LS; Tsou MY; Lee YH
Mol Neurobiol; 2019 Dec; 56(12):8451-8474. PubMed ID: 31257558
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
[TBL] [Abstract][Full Text] [Related]
5. Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Bao XQ; Wu LY; Wang XL; Sun H; Zhang D
Naunyn Schmiedebergs Arch Pharmacol; 2015 May; 388(5):549-56. PubMed ID: 25678053
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of soluble epoxide hydrolase attenuates airway remodeling in a chronic asthma model.
Jiang JX; Guan Y; Shen HJ; Jia YL; Shen J; Zhang LH; Liu Q; Zhu YL; Xie QM
Eur J Pharmacol; 2020 Feb; 868():172874. PubMed ID: 31866410
[TBL] [Abstract][Full Text] [Related]
7. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
Revermann M; Schloss M; Barbosa-Sicard E; Mieth A; Liebner S; Morisseau C; Geisslinger G; Schermuly RT; Fleming I; Hammock BD; Brandes RP
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):909-14. PubMed ID: 20224052
[TBL] [Abstract][Full Text] [Related]
8. Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.
Pallàs M; Vázquez S; Sanfeliu C; Galdeano C; Griñán-Ferré C
Biomolecules; 2020 May; 10(5):. PubMed ID: 32369955
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling.
Merkel MJ; Liu L; Cao Z; Packwood W; Young J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2010 Feb; 298(2):H679-87. PubMed ID: 20008276
[TBL] [Abstract][Full Text] [Related]
10. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.
Ren Q; Ma M; Yang J; Nonaka R; Yamaguchi A; Ishikawa KI; Kobayashi K; Murayama S; Hwang SH; Saiki S; Akamatsu W; Hattori N; Hammock BD; Hashimoto K
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5815-E5823. PubMed ID: 29735655
[TBL] [Abstract][Full Text] [Related]
11. Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model.
Sun CP; Zhou JJ; Yu ZL; Huo XK; Zhang J; Morisseau C; Hammock BD; Ma XC
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217618
[TBL] [Abstract][Full Text] [Related]
12. Epoxyeicosanoid Signaling Provides Multi-target Protective Effects on Neurovascular Unit in Rats After Focal Ischemia.
Liu Y; Wan Y; Fang Y; Yao E; Xu S; Ning Q; Zhang G; Wang W; Huang X; Xie M
J Mol Neurosci; 2016 Feb; 58(2):254-65. PubMed ID: 26545915
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease.
Zhang L; Huang L; Chen L; Hao D; Chen J
Toxicol Lett; 2013 Oct; 222(2):155-63. PubMed ID: 23911879
[TBL] [Abstract][Full Text] [Related]
14. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
Zhao Y; Zhang Q; Xi J; Xiao B; Li Y; Ma C
Int J Clin Exp Pathol; 2015; 8(3):2354-64. PubMed ID: 26045742
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection by Paeoniflorin in the MPTP mouse model of Parkinson's disease.
Zheng M; Liu C; Fan Y; Yan P; Shi D; Zhang Y
Neuropharmacology; 2017 Apr; 116():412-420. PubMed ID: 28093210
[TBL] [Abstract][Full Text] [Related]
17. Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.
Yao L; Li W; She H; Dou J; Jia L; He Y; Yang Q; Zhu J; Cápiro NL; Walker DI; Pennell KD; Pang Y; Liu Y; Han Y; Mao Z
J Biol Chem; 2012 Oct; 287(41):34246-55. PubMed ID: 22891246
[TBL] [Abstract][Full Text] [Related]
18. 14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease.
Chen W; Wang M; Zhu M; Xiong W; Qin X; Zhu X
J Neurosci; 2020 Oct; 40(42):8188-8203. PubMed ID: 32973044
[TBL] [Abstract][Full Text] [Related]
19. N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP
Luo D; Zhao J; Cheng Y; Lee SM; Rong J
Mol Neurobiol; 2018 Mar; 55(3):2258-2267. PubMed ID: 28321769
[TBL] [Abstract][Full Text] [Related]
20. Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγ.
Nayeem MA; Pradhan I; Mustafa SJ; Morisseau C; Falck JR; Zeldin DC
Am J Physiol Regul Integr Comp Physiol; 2013 Jan; 304(1):R23-32. PubMed ID: 23152114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
